

SLN MET – TO ALND OR NOT TO ALND? OR: ALND, THE END

ד"ר מיכאל קורץ
מנהל, המרכז הבריאות השד בנגב
מ.ר.א. סורוקה, ב"ש

ALND , the end.

- 1985 NSABP B-04
- ~1000 PTS RANDOMIZED +/- ALND
- 50% of axillary mets operated on later
- 1999 meta-analysis Orr R – 6 RPT ALND vs no, + small survival advantage
- **BEFORE ERA OF ADJUVANT THERAPY**

ALND, the end.

- JCO April 2009, “Comparison of SLNB alone and CALND for node-positive breast cancer”
Winchester D
- NCDB U.S. 1998-2005 97,314 pts. 20.8% only SLN
- “completion ALND does not appear to improve outcome...nonsignificant trend towards better outcomes for those with macroscopic disease”

ALND, the end.

- 2011 ACOSOG Z0011– is ALND necessary for survival or local control in patients with pos SLN in the context of BCS with XRT and adjuvant RX?
- JAMA FEB 2011 890 patients randomized after SLN + (1-2), T 1-2
- Mean follow-up of 6.3 yr. no survival difference
- Survival in both arms > 90%
- Axillary nodal recurrence < 1% in SLN arm
- Is this a practice-changing study?

ALND, the end

- For early breast cancer with small volume disease in SLN, ALND does not appear to confer any benefit in local control, DFS, or OS
- Caveats: few ER neg patients, few young, few ILC, not applicable for mastectomy without XRT or lumpectomy without XRT, neoadjuvant, limited follow-up

ALND, the end.

- Additional questions: is XRT replacing ALND? – much of axilla receives therapeutic dose
- Patient selection bias- ACOSOG poor recruitment– 70% T1 85% ER POS 35% micromets
- RPT with restricted eligibility criteria, homogenous group of patients
- Same arguments against NSABP B-06

ALND, the end.

- St. Gallen 2011 Summary of the Consensus Discussion Breast Care 2011; 6:136-141
- 47 experts voted
- If SLN pos. micromets 77% no ALND
- Panel concluded that ACOSOG data must not be extrapolated to other patients covered in ACOSOG Z0011 – only T1-2 N0 (including US)

ALND, the end

- Ann Surg Onc 9/11 M.D. Anderson – “Multidisciplinary considerations in the implementation of the findings from the ACOSOG Z0011 study: A Practice-Changing Trial
- “safely omit ALND ..who meet the eligibility criteria for Z0011”
- Eliminate need for intraoperative FS
- Nodal burden still important

ALND, the end.

- ALND – the end for many (most?) patients
- Individualize treatment
- הרבה מבקרים – תביאו ראיות ממחקרים חדשים!
- ACOSOG “old” type of trial without research\molecular biologic component
- Improved breast cancer survival – early detection, better RX – Her -2 disease
- Better results will not come from the knife